Antithrombotic Therapy in Percutaneous Atrial Structural Interventions
Konstantinos Pitsikakis1, Ioannis Skalidis2, Emmanuel Skalidis1
1Department of Cardiology, University Hospital of Heraklion, Voutes, Leof Panepistimiou, 71500 Iraklio, Greece.
Insights
Optimal antithrombotic strategies after left atrial appendage occlusion (LAAO), patent foramen ovale (PFO), and atrial septal defect (ASD) closure are uncertain. Evidence synthesis highlights inconsistent practices and the need for standardized, individualized approaches to prevent device-related thrombus.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Device Thrombosis
Background:
- Percutaneous closure of left atrial appendage (LAAO), patent foramen ovale (PFO), and atrial septal defect (ASD) require antithrombotic therapy to prevent device-related thrombus during healing.
- Current antithrombotic regimens are inconsistent across clinical practices, lacking standardized protocols.
Purpose of the Study:
- To review and synthesize current evidence on postprocedural antithrombotic strategies for LAAO, PFO, and ASD closure.
- To compare the efficacy and safety of different antithrombotic regimens.
- To identify knowledge gaps and areas for future research.
Main Methods:
- Systematic review of contemporary evidence on antithrombotic therapies post-LAAO, PFO closure, and ASD closure.
- Comparison of efficacy and safety data from observational studies and limited clinical trials.
- Analysis of current clinical practice variations and surveillance protocols.
Main Results:
- For LAAO, direct oral anticoagulants (DOACs) show promise, but device-related thrombus remains a concern, and imaging protocols vary.
- For PFO and ASD closure, antiplatelet-only strategies (dual then single) are common, with potential for simplified or abbreviated regimens.
- High-quality comparative trials are scarce, leading to ongoing debate on optimal therapy, duration, and surveillance.
Conclusions:
- Optimal antithrombotic therapy, duration, and surveillance post-atrial structural interventions remain debated.
- Standardized imaging definitions, robust randomized trials, and individualized risk-based frameworks are crucial for optimizing patient care.
- Further research is needed to establish evidence-based, personalized antithrombotic strategies.
Abstract:
Percutaneous left atrial appendage occlusion (LAAO), patent foramen ovale (PFO) closure, and atrial septal defect (ASD) closure rely on temporary antithrombotic therapy to prevent device-related thrombus during endothelialization, yet optimal regimens remain uncertain and vary widely across clinical practice. This review synthesizes contemporary evidence on postprocedural antithrombotic strategies, comparing efficacy and safety data and identifying key gaps in knowledge. After LAAO, therapeutic approaches range from short-term anticoagulation with vitamin K antagonists or direct oral anticoagulants to dual or single antiplatelet therapy in patients with high bleeding risk; observational data increasingly support DOAC-based regimens, although device-related thrombus remains a significant concern, and follow-up imaging protocols are inconsistent. Following PFO and ASD closure, antiplatelet-only regimens-typically brief dual antiplatelet therapy followed by aspirin-are widely used, with evidence suggesting that simplified or abbreviated strategies may be sufficient in selected patients. Despite extensive clinical experience, high-quality comparative trials are limited, and optimal therapy, duration, and surveillance remain debated. Standardized imaging definitions, randomized studies, and individualized risk-based frameworks are needed to optimize antithrombotic care after atrial structural interventions.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Pericarditis III: Medical Management
Heart Failure VI: Adjunct Therapies


